Abstract:【Abstract】 Objective To study the costeffectiveness analysis of bevacizumab in combination with chemotherapy for metastatic breast cancer patients in Sichuan Province based on current healthy system of China. Methods According to the result of E2100,we analysed the costeffectiveness by the cost of Sichuan province. Also we would analyse the sensitivity. Results Paclitaxel plus bevacizumab compared with paclitaxel alone, ICER was much higher than three times of the GDP. The sensitivity analysis showed that even if the price of bevacizumab decline 50%, the combination group did not have the costeffectivenss.The price of bevacizumab and the medical examination were the most important among the all parameters about the cost.Conclusion Bevacizumab had not the costeffectiveness in combination with paclitaxel for metastatic breast cancerbased on current healthy system of China.